Table 1. Characterisation of TLE3 status by baseline clinic-pathological features.
| Factor | Category | Visual IHC TLE3− (n=161) | Visual TLE3+ (n=798) | P-valuea | Ariol TLE3− (n=201) | Ariol TLE3+ (n=834) | P-valuea |
|---|---|---|---|---|---|---|---|
| Treatment | EC/T | 41 (12.9%) | 276 (87.1%) | 0.076 | 58 (16.8%) | 287 (83.2%) | 0.279 |
| CEF | 62 (18.2%) | 278 (81.8%) | 73 (19.9%) | 293 (80.1%) | |||
| AC/T | 58 (19.2%) | 244 (80.8%) | 70 (21.6%) | 254 (78.4%) | |||
| Age | <=39 | 16 (11.0%) | 129 (89.0%) | 0.050 | 23 (14.5%) | 136 (85.5%) | 0.006 |
| 60–69 | 0 (0.0%) | 15 (100%) | 0 (0.0%) | 16 (100%) | |||
| 50–59 | 61 (17.3%) | 291 (82.7%) | 92 (24.1%) | 290 (75.9%) | |||
| 40–49 | 84 (18.8%) | 363 (81.2%) | 86 (18.0%) | 392 (82.0%) | |||
| Race | White | 148 (16.8%) | 734 (83.2%) | 0.941 | 184 (19.5%) | 762 (80.5%) | 0.488 |
| Unknown | 4 (21.1%) | 15 (78.9%) | 7 (33.3%) | 14 (66.7%) | |||
| Hawiian/Pacific | 0 (0.0%) | 1 (100%) | 0 (0.0%) | 1 (100%) | |||
| Black | 2 (10.0%) | 18 (90.0%) | 5 (20.0%) | 20 (80.0%) | |||
| Asian | 5 (19.2%) | 21 (80.8%) | 4 (12.9%) | 27 (87.1%) | |||
| Aboriginal | 2 (18.2%) | 9 (81.8%) | 1 (9.1%) | 10 (90.9%) | |||
| Performance status | 2 | 2 (50.0%) | 2 (50.0%) | 0.096 | 1 (25.0%) | 3 (75.0%) | 0.959 |
| 1 | 35 (19.8%) | 142 (80.2%) | 37 (19.6%) | 152 (80.4%) | |||
| 0 | 124 (15.9%) | 654 (84.1%) | 163 (19.4%) | 679 (80.6%) | |||
| Type of surgery | Total mastectomy | 80 (17.2%) | 386 (82.8%) | 0.760 | 99 (19.8%) | 401 (80.2%) | 0.765 |
| Partial mastectomy | 81 (16.4%) | 412 (83.6%) | 102 (19.1%) | 433 (80.9%) | |||
| Number of positive nodes | >10 | 10 (17.2%) | 42 (82.8%) | 0.027 | 8 (13.3%) | 52 (86.7%) | 0.292 |
| 4–10 | 37 (17.9%) | 170 (82.1%) | 49 (21.8%) | 176 (78.2%) | |||
| 1–3 | 51 (12.8%) | 348 (87.2%) | 77 (17.7%) | 358 (82.3%) | |||
| 0 | 63 (21.4%) | 232 (78.6%) | 67 (21.3%) | 248 (78.7%) | |||
| T stage | Tx | 2 (66.7%) | 1 (33.3%) | 0.013 | 2 (66.7%) | 1 (33.3%) | 0.085 |
| T4 | 0 (0.0%) | 13 (100%) | 0 (0.0%) | 15 (100%) | |||
| T3 | 15 (16.7%) | 75 (83.3%) | 19 (19.6%) | 78 (80.4%) | |||
| T2 | 102 (19.0%) | 434 (81.0%) | 115 (20.1%) | 457 (79.9%) | |||
| T1 | 42 (13.2%) | 275 (86.8%) | 65 (18.7%) | 283 (81.3%) | |||
| Nodal status | N2 | 9 (14.3%) | 54 (85.7%) | 0.045 | 14 (20.0%) | 56 (80.0%) | 0.499 |
| N1 | 89 (14.8%) | 511 (85.2%) | 119 (18.3%) | 530 (81.7%) | |||
| N0 | 63 (21.3%) | 233 (78.7% | 68 (21.5%) | 248 (78.5%) | |||
| ER status | Positive | 50 (8.8%) | 521 (91.2%) | <0.0001 | 77 (12.7%) | 530 (87.3%) | <0.0001 |
| Negative | 111 (28.6%) | 277 (71.4%) | 124 (29.0%) | 304 (71.0%) | |||
| Menopausal status | Pre | 112 (16.9%) | 549 (83.1%) | 0.848 | 130 (18.2%) | 584 (81.8%) | 0.141 |
| Post | 49 (16.4%) | 249 (83.6% | 71 (22.1%) | 250 (77.9%) | |||
| HER2 status | Unknown | 26 (16.0%) | 137 (84.0%) | 0.228 | 31 (18.0%) | 141 (82.0%) | 0.369 |
| Positive | 2 (14.3%) | 12 (85.7%) | 3 (21.4%) | 11 (78.6%) | |||
| Negative | 3 (14.3%) | 18 (85.7%) | 7 (31.8%) | 15 (68.2%) | |||
| 3+ | 8 (8.1%) | 91 (91.9%) | 14 (13.3%) | 91 (86.7%) | |||
| 2+ | 12 (17.9% | 55 (82.1%) | 16 (22.2%) | 56 (77.8%) | |||
| 0 or 1+ | 110 (18.5%) | 485 (81.5%) | 130 (20.0%) | 520 (80.0%) | |||
| Adjuvant Rx | Yes | 116 (16.5%) | 587 (83.5%) | 0.604 | 142 (18.8%) | 615 (81.2%) | 0.373 |
| No | 45 (17.9%) | 206 (82.1%) | 58 (21.2%) | 215 (78.8%) | |||
| Missing | 0 (0.0%) | 5 (100%) | 1 (20.0%) | 4 (80.0%) | |||
| Adjuvant Endo | Yes | 49 (87%) | 516 (91.3%) | <0.0001 | 77 (12.8%) | 526 (87.2%) | <0.0001 |
| No | 112 (28.8%) | 277 (71.2%) | 123 (28.8%) | 304 (71.2%) | |||
| Missing | 0 (0.0%) | 5 (100%) | 1 (20.0%) | 4 (80.0%) | |||
| Adjuvant Herceptin | Yes | 10 (16.9%) | 49 (83.1%) | 0.988 | 13 (20.6%) | 50 (79.4%) | 0.801 |
| No | 151 (16.9%) | 744 (83.1%) | 187 (19.3%) | 780 (80.7%) | |||
| Missing | 0 (0.0%) | 5 (100%) | 1 (20.0%) | 4 (80.0%) | |||
| Histologic Grade III | Yes | 93 (20.7%) | 357 (79.3%) | 0.006 | 115 (23.9%) | 366 (76.1%) | 0.001 |
| No | 23 (11.1%) | 184 (88.9%) | 27 (11.8%) | 202 (88.2%) | |||
| Missing | 45 (14.9) | 257 (85.1) | 59 (18.2) | 266 (81.8) |
Abbreviations: ER=oestrogen receptor; IHC=immunohistochemistry. Treatment=treatment arm within MA21 study. TLE3−=TLE3 negative (as defined in materials and methods), TLE+=TLE3 positive.
a
P-value based on exact Fisher test.